Vitreous Level Of Tumor Necrosis Factor Alpha In Patients With Retinal Vein Occlusion

Vitreous Level Of Tumor Necrosis Factor Alpha In Patients With Retinal Vein Occlusion

To assess the levels of TNF- α in vitreous samples of patients with retinal vein occlusion prior to administration of intravitreal anti-VEGF and compare them to levels in vitreous samples of normal subjects so as to investigate the association of vitreous tumor necrosis factor with the pathogenesis of retinal vein occlusion.

Inclusion Criteria:

• Any patient with retinal vein occlusion not older than 6 months with no history of Anti-VEGF injection

Exclusion Criteria:

1. Diabetic patients.
2. Other causes of retinal vascular diseases.
3. Patients with history of treatment of retinal vein occlusion.
4. Previous intraocular surgery except cataract surgery performed 6 months before the study.
5. Subjects with severe systemic inflammatory diseases
6. Retinal vein occlusion secondary to retinal vasculitis.
7. All retinal pathologies.
8. Patients receiving Systemic steroids or Immunosuppressive therapy.